Inovio Pharmaceuticals Inc INO

Healthcare Biotechnology

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.

NDAQ:INO - Post by User

Inovio Pharmaceuticals Inc

Bullboard Posts

Post by Miner1967on Jul 07, 2016 2:47am

187 Views

Post# 25030472

After profits from AKAO&QLT.TO, check ABIO

I sold also QLTI (OLT.TO) after it popped with its merger news and I have started accumulating ABIO / Arca Biopharma.

ABIO is a similar with AKAO case, which offered big gains lately. ABIO trades below its book value, it is cash rich and it has a strong fast tracked candidate in collaboration with a big pharma.

Currently it trades near its lows. Technically looks that it has bottomed.

Bullboard Posts

Get a better understanding of the psychology of options trading